1.Treatment effect of blood purification combined with fasudil in elderly cardiac surgery patients with postoperative acute kidney injury
Yanmei JI ; Haoming ZHANG ; Min FANG ; Sen CHEN ; Jialong GUO
Chinese Journal of Postgraduates of Medicine 2014;37(14):1-3,38
Objective To explore the clinical effect of blood purification combined with fasudil in elderly cardiac surgery patients with postoperative acute kidney injury.Methods Fifty elderly cardiac surgery patients with postoperative acute kidney injury were divided into control group and study group by random digit table method with 25 cases each.The 2 groups were treated with routine drug and blood purification,the study group was additionally given fasudil injection 30 mg + 0.9% sodium chloride injection 50 ml vein pumping,1 time/12 h,for 7 d.The urine volume,urine N-acetyl-β-D-glucosaminidase (NAG),urine γ-glutamyl transpeptidase (γ-GTP),urine α 1-microglobulin (α 1-MG),serum creatinine (SCr),blood urea nitrogen (BUN) and creatinine clearance rate (CCr) were observed,and the acute physiology and chronic health evaluation (APACHE) Ⅱ score was computed.Results There were no statistical differences in the indexes before treatment between the 2 groups (P> 0.05).The urine volume after treatment 3,5,7 d in study group was more than that in control group [(38.72 ± 2.68) ml/h vs.(31.68 ± 2.52) ml/h,(47.24 ±3.73) ml/h vs.(40.24 ± 2.52) ml/h、(63.80 ± 2.50) ml/h vs.(56.60 ± 3.30) ml/h],urine NAG,urine α 1-MG,urine γ-GTP,SCr and BUN were lower than those in control group [NAG:(25.05 ±5.44) U/L vs.(28.04 ± 5.21) U/L,(24.06 ± 3.43) U/L vs.(27.23 ± 6.43) U/L,(22.08 ± 3.25) U/L vs.(26.23 ± 4.41) U/L; α 1-MG:(24.05 ± 3.65) mg/L vs.(26.74 ± 6.74) mg/L,(22.98 ± 3.58) mg/L vs.(25.57 ± 3.58) mg/L,(20.95 ± 3.78) mg/L vs.(25.48 ± 3.45) mg/L; γ-GTP:(8.2 ± 0.4) U/L vs.(10.8 ± 3.8) U/L,(7.3 ± 0.2)U/L vs.(10.5 ± 2.5) U/L,(6.5 ± 1.4) U/L vs.(9.7 ± 2.6) U/L; SCr:(206.52 ± 6.72) μ mol/L vs.(255.16 ±6.75) μmol/L,(182.98 ±6.26) μmol/L vs.(252.23 ±9.53) μmol/L,(33.25 ±7.95) μmol/L vs.(170.75 ± 7.94) μ mol/L; BU N:(19.61 ± 3.23) mmol/L vs.(20.25 ± 3.25) mmol/L,(16.76 ± 2.06) mmol/L vs.(18.32 ± 4.84) mmol/L,(12.28 ± 2.26) mmol/L vs.(14.27 ± 4.54) mmol/L],CCr was higher than that in control group [(18.66 ± 3.89) ml/min vs.(13.28 ± 3.25) ml/min,(27.76 ± 4.36) ml/min vs.(16.23 ± 4.18)ml/min,(33.79 ± 5.58) ml/min vs.(22.12 ± 4.65) ml/min],there were statistical differences (P < 0.05).The APACHE Ⅱ score before treatment and after treatment 5,7 d in control group were (32.20 ±4.51),(26.38 ±5.28) and (21.43 ±4.22) scores,in study group were (33.05 ±3.82),(22.15 ±3.42) and (13.25 ± 2.15) scores.There was no statistical difference in the APACHE Ⅱ score before treatment (P > 0.05),the APACHE Ⅱ score after treatment was improved,furthermore APACHE Ⅱ score after treatment 5,7 d in study group were better than those in control group,there were statistical differences (P < 0.05).Conclusions The treatment effect of blood purification combined with fasudil is remarkable in elderly cardiac surgery patients with postoperative acute kidney injury.At the same time,it has high security and very important clinical significance.
2.Relationship between serum ferritin, erythrocyte sedimentation rate, mean corpuscular indexes and prognosis in patients with small cell lung cancer
Jinhua XIE ; Haoming JI ; Guodong CHEN ; Yu WANG ; Yucheng SHEN
Journal of International Oncology 2018;45(8):465-469
Objective To explore the clinical value of serum ferritin (SF),erythrocyte sedimentation rate (ESR) and erythrocyte average indexes [mean corpuscular volume (MCV),mean corpuscular hemoglobin (MCH),mean corpuscular hemoglobin concentration (MCHC)] in the prognosis evaluation of patients with small cell lung cancer (SCLC).Methods A total of 72 SCLC patients were enrolled in the Haian People's Hospital Affiliated to Nantong University from January 2013 to October 2016 (SCLC group),and 80 health controls were selected at the same time (control group).The levels of serum SF,ESR and erythrocyte average indexes in SCLC group and control group were detected,and their relationships with clinical features,prognosis and survival time were analyzed.Results The serum levels of SF,ESR,MCV,MCH and MCHC in SCLC patients were (309 ±59) μg/L,(16 ±4) mm/h,(104 ± 12) fl,(32 ±4) pg and (307 ±21) g/L,respectively.The serum levels of SF,ESR,MCV,MCH and MCHC in control group were (186 ±26) μg/L,(15 ±5)mm/h,(85 ± 7) fl,(30 ± 3) pg and (335 ± 25) g/L,respectively.Compared with the control group,the patients in SCLC group were significantly increased on the levels of SF (t =14.168,P < 0.001) and MCV (t =6.143,P < 0.001),and were significantly decreased on the level of MCHC (t =-4.220,P =0.003).There were no significant difference in the levels of ESR (t =1.931,P =0.102) and MCH (t =1.220,P =0.313) between the two groups.The serum levels of SF and MCV were significantly correlated with the stage of SCLC (t =-4.092,P =0.009;t =-4.985,P < 0.001).Multivariate logistic regression analysis showed that high serum SF (OR =5.31,95% CI:3.09-9.31,P < 0.001) and MCV (OR =1.78,95% CI:1.10-3.08,P =0.013) were independent risk factors of SCLC.Survival analysis showed that the survival time of the patients in the high SF group was significantly shorter than that in the low SF group (6 months vs.20 months;x2 =6.556,P =0.001).Conclusion Serum ESR,MCH and MCHC levels are not significantly correlated with SCLC,but serum SF and MCV levels are of important clinical significance in evaluating the prognosis of SCLC patients.
3.Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, multi-center, double-blind, double-dummy, active-controlled, randomized trial
Changyu PAN ; Qiuhe JI ; Wenying YANG ; Ping FENG ; Chao LIU ; Shengli YAN ; Yan GAO ; Jianping WENG ; Xin GAO ; Guang NING ; Zhimin LIU ; Haoming TIAN ; Weiping JIA ; Li YAN ; Yaoming XUE ; Yinzhang WANG ; Xiaohui GUO
Chinese Journal of Endocrinology and Metabolism 2009;25(4):386-390
inal event.
4.Efficacy and safety of glimepiride as initial treatment in newly-diagnosed patients with type 2 diabetes mellitus : sub-group analysis of GREAT study
Xiaohui GUO ; Xiaofeng Lü ; Ping HAN ; Xiuzhen ZHANG ; Huazhang YANG ; Wenruo DUAN ; Shengli YAN ; Zhongyan SHAN ; Qing SU ; Liming CHEN ; Jianling DU ; Qinhua SONG ; Yongde PENG ; Xingbo CHENG ; Qifu LI ; Haoming TIAN ; Jian WANG ; Qiuhe JI ; Yan GAO
Chinese Journal of Endocrinology and Metabolism 2012;(12):979-983
Objective To analyze the efficacy and safety of glimepiride treatment as initial monotherapy in newly diagnosed patients with type 2 diabetes mellitus (T2DM).Methods This was a subgroup analysis of the GREAT study,which investigated the efficacy and safety of glimepiride as initial monotherapy in Chinese patients with T2DM.This analysis was performed in 209 patients with disease duration less than 6 months and never received any anti-diabetic drugs.The change of HbA1C,fasting plasm glucose (FPG),2 h postprandial blood glucose (2hPPG),homeostasis model assessment for β-cell function index (HOMA-β),homeostasis model assessment for insulin-resistance index(HOMA-IR),the percentage of patients with HbA1C < 7.0% at endpoint and the incidence of hypoglycemia were evaluated after 16-weeks treatment.Results After 16-weeks glimepiride treatment,HbA1C value reduced significantly from baseline to endpoint,the reduction was statistically significant (9.21% ± 1.65% to 6.69%±0.83%,P<0.001),69.7% of the patients achieved HbA1C <7.0% at study endpoint.Glimepiride-treated patients also achieved a significant improvement in FPG [from (10.15 ± 2.13) mmol/L to (7.23 ± 1.50) mmol/L,P<0.001] and 2hPPG [from (17.21 ±4.14) mmol/L to (11.62 ± 3.34) mmol/L].HOMA-β was improved from 17.21± 15.19 [11.62 (2.90,115.8)] to 41.13 ± 44.12 [28.00 (5.1,360.00)],and HOMA-IR was reduced from 2.32± 1.90 [1.76 (0.60,12.80)] to 2.07 ± 1.74 [1.63 (0.4,12.3)].The incidence of all reported symptomatic hypoglycemia was 18.2%,and the incidence of confirmed hypoglycemia was 3.8%.Conclusion This analysis showed that glimepiride treatment as an initial mono-therapy could effectively improve blood glucose control in newly diagnosed patients with T2DM,and the treatment may improve islet β cell function,and the safety profile is reasonably good.